CHICAGO: Amgen and Novartis have signed a deal to co-develop and commercialise a range of new Alzheimer’s disease and migraine drugs.
In Alzheimer’s disease the firms will work together on BACE inhibitor programs, with Novartis’ phase I/II candidate CNP520 as the lead molecule.
CNP520 is an oral BACE inhibitor designed to prevent the production of different types of amyloid in the brain that could potentially stop, slow or delay symptoms typically associated with Alzheimer’s, said David Epstein, head of Novartis.